JP2003514770A5 - - Google Patents

Download PDF

Info

Publication number
JP2003514770A5
JP2003514770A5 JP2001522958A JP2001522958A JP2003514770A5 JP 2003514770 A5 JP2003514770 A5 JP 2003514770A5 JP 2001522958 A JP2001522958 A JP 2001522958A JP 2001522958 A JP2001522958 A JP 2001522958A JP 2003514770 A5 JP2003514770 A5 JP 2003514770A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
disease
composition according
compound
glycero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001522958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003514770A (ja
Filing date
Publication date
Priority claimed from IL13188799A external-priority patent/IL131887A0/xx
Application filed filed Critical
Publication of JP2003514770A publication Critical patent/JP2003514770A/ja
Publication of JP2003514770A5 publication Critical patent/JP2003514770A5/ja
Pending legal-status Critical Current

Links

JP2001522958A 1999-09-14 2000-09-13 抗増殖性医薬の燐脂質プロドラッグ Pending JP2003514770A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL131887 1999-09-14
IL13188799A IL131887A0 (en) 1999-09-14 1999-09-14 Phospholipid prodrugs of anti-proliferative drugs
PCT/IL2000/000562 WO2001019320A2 (en) 1999-09-14 2000-09-13 Phospholipid prodrugs of anti-proliferative drugs

Publications (2)

Publication Number Publication Date
JP2003514770A JP2003514770A (ja) 2003-04-22
JP2003514770A5 true JP2003514770A5 (enExample) 2007-10-11

Family

ID=11073248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001522958A Pending JP2003514770A (ja) 1999-09-14 2000-09-13 抗増殖性医薬の燐脂質プロドラッグ

Country Status (9)

Country Link
US (1) US6774121B1 (enExample)
EP (1) EP1218013A4 (enExample)
JP (1) JP2003514770A (enExample)
AU (1) AU781507B2 (enExample)
CA (1) CA2382633A1 (enExample)
IL (2) IL131887A0 (enExample)
NZ (1) NZ517522A (enExample)
WO (1) WO2001019320A2 (enExample)
ZA (1) ZA200201081B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
EP0781138B1 (en) 1994-08-29 2008-05-21 Wake Forest University Lipid analogs for treating viral infections
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
PL367102A1 (en) 2001-05-02 2005-02-21 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US7410956B2 (en) * 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
AU2003231765B9 (en) 2002-04-26 2010-01-28 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
PL1628685T3 (pl) 2003-04-25 2011-05-31 Gilead Sciences Inc Przeciwwirusowe analogi fosfonianowe
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
JP2006524710A (ja) 2003-04-25 2006-11-02 ギリアード サイエンシーズ, インコーポレイテッド キナーゼインヒビターホスホネート抱合体
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
EP1629281B1 (en) 2003-05-30 2008-10-29 Purdue Research Foundation Diagnostic method for atherosclerosis
AU2004286239A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
WO2005044308A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
DE602004019815D1 (de) 2003-12-22 2009-04-16 Gilead Sciences Inc 4'-substituierte carbovir- und abacavir-derivate sowie verwandte verbindungen mit hiv- und hcv-antiviraler wirkung
EP1778251B1 (en) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
JP5175723B2 (ja) 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
DE102006019907A1 (de) * 2006-04-28 2007-10-31 Müller-Enoch, Dieter, Prof. Dr. Verwendung von substituierten Glycerinderivaten zur Herstellung einer pharmazeutischen Zubereitung
US8685752B2 (en) 2006-11-03 2014-04-01 Purdue Research Foundation Ex vivo flow cytometry method and device
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
US8961926B2 (en) 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
AU2009268681B2 (en) 2008-07-08 2014-10-02 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2563401A1 (en) * 2010-04-30 2013-03-06 Telormedix SA Methods for inducing an immune response
WO2011134668A1 (en) * 2010-04-30 2011-11-03 Telormedix Sa Phospholipid drug analogs
US20130244982A1 (en) * 2010-12-02 2013-09-19 Bengurion University Of The Negev Research And Development Authority Conjugates of a phospholipid and a drug for the treatment of inflammatory bowel disease
US9499800B2 (en) 2013-12-26 2016-11-22 Regents Of The University Of Minnesota Methods of making and using chemically self assembled-nanorings
SI3750545T1 (sl) * 2014-11-17 2024-06-28 Cellectar Biosciences, Inc. Analogi fosfolipidnega etra kot nosilci zdravil, ki ciljajo na raka
EP3661937B1 (en) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
WO2019200043A1 (en) * 2018-04-11 2019-10-17 New Mexico Tech University Research Park Coporation Lipid prodrugs for use in drug delivery
WO2025202629A1 (en) 2024-03-26 2025-10-02 Coopervision International Limited Contact lens loaded with a glycerophospholipid

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61152694A (ja) * 1984-12-27 1986-07-11 Toyama Chem Co Ltd 新規な5−フルオロ−2′−デオキシウリジン−5′−ホスフエ−ト誘導体およびその塩
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
ES2035824T3 (es) 1986-03-14 1993-05-01 Fujisawa Pharmaceutical Co., Ltd. Procedimiento para preparar compuestos profarmacos y preparaciones que los contienen.
JPS6383093A (ja) * 1986-09-27 1988-04-13 Toyo Jozo Co Ltd ヌクレオシド−リン脂質複合体
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
AU668873B2 (en) 1991-07-12 1996-05-23 Chimerix, Inc. Antiviral liponucleosides: treatment of hepatitis B
IL105244A (en) 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US7517858B1 (en) * 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
CA2262624A1 (en) * 1996-08-02 1998-02-12 Smithkline Beecham Corporation A novel method of detecting and treating cancer
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
CA2320843A1 (en) * 1998-02-23 1999-08-26 Diadexus, Llc Methods using pla2 as a marker of metastases and for the diagnosis of selected cancers

Similar Documents

Publication Publication Date Title
US10570123B2 (en) Pharmacokinetically improved compounds
US6774121B1 (en) Phospholipid prodrugs of anti-proliferative drugs
US9255106B2 (en) Substituted [1,2,4]triazolo[4,3-a]pyrazines as PARP-1 inhibitors
US9096627B2 (en) Hydroxamic acid derivatives
TWI508725B (zh) 脂肪酸富馬酸酯衍生物及其用途
ES2249884T3 (es) Derivados del acido indolil-3-glioxilico con efecto antitumoral.
JP2006523202A (ja) 生体還元により活性化されるプロドラッグ
US20120202793A1 (en) Rho kinase inhibitors
TWI736578B (zh) 6-5元稠合唑環衍生物及其藥物組合物,以及作為藥物的應用
CN102131812A (zh) 吡咯并[2,3-d]嘧啶化合物
CN1938307A (zh) 9-取代的8-氧化腺嘌呤
BR122023027277A2 (pt) Derivados deuterados de ruxolitinib e composição farmacêutica
JP2021519297A (ja) Trkキナーゼ阻害剤としての大環状化合物
US7902359B2 (en) Decahydronaphthalene compounds
US20210380626A1 (en) Novel small molecule drug conjugates of gemcitabine derivatives
CN113372366A (zh) 一种吡咯并嘧啶类化合物的盐、其晶型及其应用
KR20020065341A (ko) 포스포디에스트라스(phosphodiesterase, PDE) Ⅳ 억제작용을 가진 푸린 유도체
US20020198218A1 (en) Synthesis and methods of use of tetrahydroindolone analogues and derivatives
ES2914355T3 (es) Inhibidores bicíclicos de la histona desacetilasa
TW201805290A (zh) 一類蛋白激酶抑制劑
US12275738B2 (en) CDK9 inhibitors
TW202019887A (zh) 酚系trpv1促效劑之聚乙二醇化前藥
EP1480984B9 (en) Hexacyclic compounds
US11129899B1 (en) Methotrexate derivatives and uses thereof
US20260022120A1 (en) Inhibitors of MENIN-MLL Interaction